 - Female patients of childbearing potential and male patients able to father children who have female partners of childbearing potential must agree to use one highly effective method defined as less than 1 failure rate per year and one additional effective method of contraception Appendix 4 from 15 days prior to first trial treatment administration until at least 60 days after study participants final dose of avelumab. 